FDA 483 - Mobeen Mazhar, M.D. - April 28, 2022

An FDA inspection of Mobeen Mazhar, M.D., Clinical Investigator, revealed significant non-compliance with clinical investigation protocols. The firm failed to properly conduct the study, report adverse events, and maintain adequate investigational drug disposition records. These issues indicate serious deficiencies in the oversight and execution of the clinical trial.